Heart failure (HF) is a major public health concern, affecting more than 5.5 million Americans, with over 550,000 new cases diagnosed each year, and accounting for up to 10% of all hospital admissions. Depression is the most robust behavioral predictor of morbidity and premature mortality among patients with symptomatic HF, with an incidence ranging from 20% to 45%, depending on HF severity. Our ongoing project HL-073355 is examining the pathophysiology associated with depression in HF patients. Few studies have systematically examined the development and progression of depression concurrent with the development of and progression to symptomatic HF and its associated neuroimmune and behavioral mechanisms. By enrolling individuals at risk for developing symptomatic HF but who are currently asymptomatic, namely American College of Cardiology/American Heart Association (ACC/AHA) Stage B patients, this competing renewal of HL-073355 will prospectively track the incidence and time course of depressive symptoms and Major Depressive Disorder (MDD), the development of symptomatic HF, potential neuroimmune and behavioral mechanisms linking HF and MDD, and associations with cardiovascular clinical outcomes. We will enroll 522 high-risk (defined as BNP >100pg/ml) ACC/AHA Stage B patients, study them at intake, and every 6 months for an average of 30 months. Through our strong collaborations with the HF teams at the University of California, San Diego (UCSD) Hillcrest and La Jolla Medical Centers, and the Veterans Affairs San Diego Healthcare System (VASDHS) in La Jolla, we have access to a large number of asymptomatic Stage B patients. Clinical assessments will include echocardiography and characterization of depressive symptoms by the Beck Depression Inventory (BDI) and the Structured Clinical Interview for DSM Disorders (SCID). Neuroimmune assessments will include circulating levels of BNP, CRP, TNF-?, IL-1?, IL-6, sICAM-1, sP-selectin, catecholamines, and functional assessments of leukocytes. In addition to depression, other behavioral and psychosocial assessments will include sleep, health behaviors (e.g., smoking, physical activity), psychosocial stressors, coping, anxiety, social network, and quality of life. Clinical outcomes will include transition from asymptomatic cardiac dysfunction to symptomatic Stages C and/or D HF, clinical cardiovascular outcomes (combined hospitalizations for cardiovascular events and/or death), and the development or recurrence of MDD. Findings from this prospective study have the potential to add new insights into how MDD might contribute to HF progression at early stages of the disease. A greater understanding of the role and mechanisms by which MDD may impact HF at this stage could support clinically relevant early MDD intervention efforts at a point when effective depression treatment could have a potentially greater impact on the course of HF.
Depression is the most robust behavioral predictor of morbidity and premature mortality among patients with heart failure, although the mechanisms of this relationship are poorly understood. In a cohort of American College of Cardiology/American Heart Association (ACC/AHA) classification asymptomatic Stage B patients, we will prospectively track depressive symptoms, the development and progression to symptomatic Stages C/D heart failure, and associations with adverse clinical cardiovascular outcomes, as well as determine potential neuroimmune and behavioral and psychosocial mechanisms within a naturalistic framework.
|von Kanel, Roland; Natarajan, Loki; Ancoli-Israel, Sonia et al. (2013) Effect of continuous positive airway pressure on day/night rhythm of prothrombotic markers in obstructive sleep apnea. Sleep Med 14:58-65|
|Edwards, K M; Wilson, K L; Sadja, J et al. (2011) Effects on blood pressure and autonomic nervous system function of a 12-week exercise or exercise plus DASH-diet intervention in individuals with elevated blood pressure. Acta Physiol (Oxf) 203:343-50|
|Edwards, Kate M; Tomfohr, Lianne M; Mills, Paul J et al. (2011) Macrophage migratory inhibitory factor (MIF) may be a key factor in inflammation in obstructive sleep apnea. Sleep 34:161-3|
|Nation, Daniel A; Hong, Suzi; Jak, Amy J et al. (2011) Stress, exercise, and Alzheimer's disease: a neurovascular pathway. Med Hypotheses 76:847-54|
|Jimenez, Jessica A; Greenberg, Barry H; Mills, Paul J (2011) Effects of Heart Failure and its Pharmacological Management on Sleep. Drug Discov Today Dis Models 8:161-166|
|Shoucri, Bassem M; Edwards, Kate M; Schmid-Schonbein, Geert W et al. (2011) Plasma-stimulated pseudopod formation is increased in patients with elevated blood pressure. Hypertens Res 34:787-9|
|Edwards, K M; Sheu, B; Hong, S et al. (2010) Leukocyte membrane bleb and pseudopod formation in hypertension. J Hum Hypertens 24:684-6|
|von Kanel, Roland; Natarajan, Loki; Ancoli-Israel, Sonia et al. (2010) Day/Night rhythm of hemostatic factors in obstructive sleep apnea. Sleep 33:371-7|
|Wirtz, Petra H; Redwine, Laura S; Linke, Sarah et al. (2010) Circulating levels of soluble intercellular adhesion molecule-1 (sICAM-1) independently predict depressive symptom severity after 12 months in heart failure patients. Brain Behav Immun 24:366-9|
|Wirtz, Petra H; Redwine, Laura S; Hong, Suzi et al. (2010) Increases in B-type natriuretic peptide after acute mental stress in heart failure patients are associated with alcohol consumption. J Stud Alcohol Drugs 71:786-94|
Showing the most recent 10 out of 25 publications